Companies exchange technologies to facilitate product discovery for use in agrochemicals, pest control and animal health, as well as human pharmaceutical applications
F2G, specialist in research and development of new treatments for
serious fungal infections in man, has entered into a research
collaboration with Dow AgroSciences, a provider of pest
management and biotechnology products to improve the quality and
quantity of food supplies.
This collaboration will allow both
companies to exchange proprietary chemistry, technology, and
expertise facilitating the discovery of novel products.
AgroSciences will develop any resulting leads suitable for use in
agrochemicals, pest control and animal health, while F2G will
concentrate on developments that have pharmaceutical
Dow AgroSciences will make selected compound
libraries available for F2G to screen for activity against human
fungal pathogens; both companies together will synthesise new
compounds, which F2G will screen for pharmaceutical potential and
Dow AgroSciences for agrochemical utility.
Novel fungal targets
identified by Dow AgroSciences will be available to F2G, which in
turn will help Dow AgroSciences in further target and screen
F2G will utilise the Dow AgroSciences' screens
for its proprietary compound libraries and those it has access
to, in the search for human antifungals.
"We recognise F2G
as a company with focus and depth of expertise in human
antifungals ranging from its genomic technology to its detailed
understanding of the market, and we are very pleased to be
collaborating with it in developing the potential of our
chemistry in such an important market," said Jim Renga,
global leader external technology, Dow AgroSciences.
Cooper from F2G said: " We are delighted to be working on
this collaboration with such a world-renowned company as Dow
AgroSciences and are pleased that they have recognised the
specialist capabilities of F2G which can bring significant
benefits to their fungicide discovery plans.
We hope and
anticipate that this initial collaboration will lead to a
fruitful and ongoing relationship between the two companies,
resulting in an expanded range of products that can be discovered
for both the pharmaceutical and agrochemical markets.
partnership marks another important step in F2G's growth
from research and development into a fully commercial drug